New screening platform leads to discovery of next-generation prodrugs for type 1 diabetes

December 16, 2020

With nearly 2 million Americans battling type 1 diabetes, it is no surprise that clinical therapies for the disease are constantly evolving and improving. In type 1 diabetes mellitus, the body's immune system attacks and destroys insulin-producing β-cells. As a result, people living with type 1 diabetes lose insulin secretion and encounter difficulty regulating glucose levels -- especially after meals. Drugs developed to proliferate β-cells often are inefficient and have off-target effects that can dysregulate other cell types and pancreatic hormone production. To address these issues, researchers at Brigham and Women's Hospital and the Broad Institute teamed up to design next-generation β-cell-targeting proliferators: zinc-binding prodrugs (ZnPD). To achieve this, the researchers engineered a new screening platform, the Disque Platform, to better represent β-cells in the lab. Utilizing the Disque Platform, researchers identified a ZnPD drug which exhibited a 2.4-fold increase in β-cell numbers in culture, out-performing its native drug, harmine, and avoiding off-target effects. Results are published in Science Advances.

"We exploited a unique feature of β-cells, which contain at least a million-fold more intracellular zinc ions than other cell types for insulin processing," said Amit Choudhary, PhD, a member of the Brigham's divisions of Renal Medicine and Engineering in Medicine and an associate member of the Broad Institute. "The ZnPD leverages principles in chemical biology to switch on the proliferators specifically in β-cells, preventing unwanted proliferation in other cell types and systemic cytotoxicity while promoting sustained β-cell proliferation."

With no durable and effective treatments for β-cell loss, researchers capitalized on this high zinc concentration in β-cells to guide their drug development. "Our novel drug type attaches an inactive β-cell proliferator to both a molecule with high affinity for zinc, known as a chelator, and a linker molecule, whose job is to stabilize the overall chemical structure," said Kisuk Yang, PhD, a postdoctoral fellow in the Karp Lab. Upon zinc binding to the chelator, the β-cell proliferator is released and begins promoting the proliferation of β-cells. However, another challenge faced by the researchers when testing the safety and efficacy of ZnPDs was the lack of accurate screening method.

Conventional screening platforms cannot reproduce the exceptionally high levels of zinc ions found in β-cells, which was essential in the design of ZnPDs. Alternatively, 3D culture systems preserve morphological and biological complexity, but are expensive and complex, and thus impractical for use in drug screening.

"To overcome these challenges, we engineered the Disque Platform: a new screening platform which combines 2D simplicity with 3D architecture. In this platform, cells are shaped into thin discs, which can accommodate both conventional 2D well plates and 3D bioreactors," said Peter Jones, a previous graduate student at Karp Lab and co-first author.

In developing the ZnPD mechanism of action, researchers looked to harmine, a type 1 diabetes drug recently found to induce β-cell proliferation but with toxic effects. Using the Disque Platform, the researchers screened multiple ZnPDs and identified a novel hit that exhibited a 2.4-fold increase in the generation of β-cells compared to harmine. Importantly, this ZnPD did not exhibit off-target effects and toxicities. The ZnPD represents a novel, chemical-biology-based drug carrier for targeted cell delivery.

"The Disque Platform can support rapid and cost-effective production of disc-shaped pseudo-islets in vitro that can be used to discover more effective drugs, and to advance a long-term cell transplantation strategy for diabetic therapy," said Jeff Karp, PhD, head of The Karp Lab and member of the Brigham's Department of Anesthesiology and Perioperative Pain Medicine. Karp is also an associate member of the Broad Institute. "In the future, the Disque Platform may be adapted to culturing other islet types or small-scale organoids for reliable drug screening applications. The implications for both this novel ZnPD and the Disque Platform are widespread, spanning beyond diabetes research."
-end-
This work was supported by the Burroughs Wellcome Fund (Career Award at the Scientific Interface) and NIH (UC4DK116255 and R01 DK113597). National Institutes of Health (Human Islet Research Network-Consortium on Human Islet Biomimetics, HIRN-CHIB) (UC4DK104165) and the Harvard Stem Cell Institute.

Choudhary is an inventor on an international patent that claims inventions related to targeted delivery to β-cells filed by the Broad Institute (no. PCT/US2018/028660). Karp, Choudhary, Yang and Jones are inventors on a patent application related to this work filed by Brigham and Women's Hospital and the Broad Institute (no. 63/039,863, filed 16 June 2020). Karp has been a paid consultant and/or equity holder for companies including Mesoblast and holds equity in Frequency Therapeutics, a company that has licensed intellectual property (IP) generated by Karp that may benefit financially if the IP is further validated.

Paper Cited:
Yang, Kisuk, Jones, Peter Anthony, Karp, Jeff, et al. "A 3D culture platform enables development of zinc-binding prodrugs for targeted proliferation of β cells" Science Advances DOI: 10.1126/sciadv.abc3207

Brigham and Women's Hospital

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.